Loading...
•
Jun 30, 2022
4DMT Q2 2022 Earnings Report
Reported second quarter 2022 financial results and provided corporate updates.
Key Takeaways
4D Molecular Therapeutics reported second quarter 2022 financial results. The company's cash, cash equivalents and marketable securities were $261.6 million as of June 30, 2022, expected to fund operations into the first half of 2025. Total revenue for the quarter was $0.2 million, and the net loss was $28.1 million.
Five clinical-stage product candidates on track for multiple clinical data updates in 2023
Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025
4D-310 Phase 1/2 clinical trial eligible patient population expanded to include females with Fabry disease
The 4D-310 Phase 1/2 clinical trial is enrolling patients concurrently across 3 cohorts at the 1E13 vg/kg dose level.
4DMT
4DMT
4DMT Revenue by Segment
Revenue by Segment
Collaboration & license rev. Revenue
CapyFin.com Forward Guidance
This press release contains forward-looking statements regarding plans and timelines for the clinical development of 4D-310, 4D-125, 4D-110, 4D-150 and 4D-710, including the therapeutic potential and clinical benefits thereof; the implications of clinical data for 4D-310’s Phase 1/2 clinical trial.